Shopping Cart

Your shopping cart is currently empty

SN50

Name: SN50
Brand: TargetMol
SKU: T12942
Price: 88 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T12942Cas No. 213546-53-3

SN50 is a cell permeable NF-κB translocation inhibitor.

SN50

Copy Product Info

😃Good

Purity: 99.91%

Catalog No. T12942Cas No. 213546-53-3

SN50 is a cell permeable NF-κB translocation inhibitor.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$88	-	In Stock
5 mg	$313	-	In Stock
10 mg	$467	-	In Stock
25 mg	$752	-	In Stock
50 mg	$987	-	In Stock
100 mg	$1,380	-	In Stock
200 mg	$1,870	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.91%

Appearance:Solid

Color:White

Resource Download

COA HPLC MS

Product Introduction

Bioactivity

Description	SN50 is a cell permeable NF-κB translocation inhibitor.
In vitro	Compared with vehicle-treated groups,pretreatment with SN50 results in a significant reduction in amount of PI-positive cells at 12, 24, and 48 h time-point post TBI [1]. Local SN50 inhibits the activation of nuclear factor-κB in local cells and reduces the occurrence of epithelial defects/ulcers during corneal healing. Myofibroblast generation, macrophage invasion, activity of matrix metalloproteinases, basement membrane destruction, and expression of cytokines are all decreased in treated corneas compared with controls[2]. Treating the human gastric cancer cells SGC7901 with SN50 could significantly enhance the effects of LY294002 on inducing cell death after 24 h[3]. SN50 can inhibit translocation of NF-kB and production of inflammatory cytokines that are implicated in lipopolysaccharide (LPS)-induced lung injury[4].
In vivo	SN50 enhances motor function recovery from the first to the fourth day and shows a significant reduction in visuospatial learning latencies on the seventh and eighth days post-TBI, compared to the control group. Furthermore, SN50 pretreatment significantly decreases NF-κB p65 and TNF-a protein levels between 6 to 48 hours post-TBI[1].

Chemical Properties

Molecular Weight	2781.5
Formula	C₁₂₉H₂₃₀N₃₆O₂₉S
Cas No.	213546-53-3
Smiles	C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C)N)=O)C)=O)C(C)C)=O)C)=O)CC(C)C)=O)CC(C)C)(=O)N1[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N2[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N3[C@H](C(O)=O)CCC3)CCSC)=O)CC(C)C)=O)CCCCN)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CCCCN)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)C(C)C)=O)CCC2)C)=O)CC(C)C)=O)CC(C)C)=O)C)=O)CC(C)C)=O)CC(C)C)=O)C(C)C)=O)C)=O)CCC1
Relative Density.	1.36 g/cm3 (Predicted)
Sequence	Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro
Sequence Short	AAVALLPAVLLALLAPVQRKRQKLMP

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 40 mg/mL (14.38 mM), Sonication is recommended.

DMSO: 80 mg/mL (28.76 mM), Sonication is recommended.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	0.3595 mL	1.7976 mL	3.5952 mL	17.9759 mL
5 mM	0.0719 mL	0.3595 mL	0.7190 mL	3.5952 mL
10 mM	0.0360 mL	0.1798 mL	0.3595 mL	1.7976 mL

DMSO

	1mg	5mg	10mg	50mg
20 mM	0.0180 mL	0.0899 mL	0.1798 mL	0.8988 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc